Neurocrine (NBIX) | Stock Overview & Key Data

Neurocrine Biosciences Inc. | Healthcare

US$120.27

1.25%

| Compare Stocks:

Neurocrine vs Zoetis Neurocrine vs Haleon Plc - ADR Neurocrine vs Intra-Cellular Neurocrine vs United Therapeutics Neurocrine vs Viatris Neurocrine vs S&P 500 | Market

Neurocrine Performance Comparison

Loading chart data...

Neurocrine

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: US$117.40 High: US$120.40

on May 15, 2025

52 Week Range

Low: US$84.23 High: US$157.98

on April 9, 2025

on August 1, 2024

All-Time High: US$157.98 on July 29, 2024

Key Statistics

Market Cap i $11.9B

EPS i 2.95

P/E Ratio (TTM) i 40.82

Forward P/E i 19.39

P/B Ratio i 4.70

PEG Ratio i 19.39

Div. Yield i 0.00%

ROE i 12.43%

Beta i 0.258

Debt to Equity i 19.45

Financial Highlights

Profitability

Gross Margin i 98.39%

Operating Margin i 4.14%

Profit Margin i 12.68%

Returns and Earnings

Return on Assets (TTM) i 8.75%

Return on Equity (TTM) i 12.43%

EBITDA i $509.4M

Net Income (TTM) i $305.8M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Neurocrine NBIX	11.92B Large-cap	2.33%	25.06%	5.52%	2.40%	-12.77%	-15.50%	39.51%	-3.66%
Zoetis ZTS	72.09B Large-cap	-0.83%	7.45%	2.47%	-8.45%	-1.40%	-7.89%	-1.37%	23.23%
Haleon Plc - ADR HLN	48.10B Large-cap	1.04%	5.53%	6.91%	13.74%	13.14%	22.91%	41.16%	41.16%
Intra-Cellular ITCI	14.05B Large-cap	0.14%	0.45%	56.54%	81.59%	56.54%	92.68%	104.13%	700.67%
United Therapeutics UTHR	14.02B Large-cap	-1.32%	6.71%	-18.48%	-16.33%	-15.63%	10.65%	61.14%	158.13%
Viatris VTRS	10.36B Large-cap	-3.19%	17.65%	-18.97%	-31.41%	-29.15%	-19.85%	-25.42%	-43.73%

Ownership & Short Interest

Insider Ownership i 1.08%

Institutional Ownership i 97.29%

Shares Short i 4M

Short Ratio i 2.53

Short % of Shares Outstanding i 6.05%

Average 10-Day Volume i 2M

Average 90-Day Volume i 2M

Neurocrine Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Neurocrine would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is NBIX's 52-week high and low?

In the last 52 weeks, Neurocrine reached a high of US$157.98 (on August 1, 2024) and a low of US$84.23 (on April 9, 2025).

What is the market cap and P/E ratio for NBIX?

Curious about Neurocrine's size and valuation? Its market capitalization stands at 11.92B. When it comes to valuation, the P/E ratio (trailing twelve months) is 40.82, and the forward P/E (looking ahead) is 19.39.

Does NBIX pay dividends? If so, what's the yield?

As for dividends, Neurocrine isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Neurocrine's main competitors or similar companies to consider before investing?

When looking at Neurocrine, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Zoetis ZTS	72.09B	Healthcare	Drug Manufacturers - Specialty & Generic	-7.89%	-1.37%
Haleon Plc - ADR HLN	48.10B	Healthcare	Drug Manufacturers - Specialty & Generic	22.91%	41.16%
Intra-Cellular ITCI	14.05B	Healthcare	Drug Manufacturers - Specialty & Generic	92.68%	104.13%
United Therapeutics UTHR	14.02B	Healthcare	Drug Manufacturers - Specialty & Generic	10.65%	61.14%
Viatris VTRS	10.36B	Healthcare	Drug Manufacturers - Specialty & Generic	-19.85%	-25.42%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Neurocrine Biosciences Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Neurocrine's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 12.43%, the Debt to Equity ratio from the most recent quarter is 19.45, and its Gross Profit Margin stands at 98.39%.

What is the recent revenue and earnings growth for NBIX?

Looking at Neurocrine's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 11.10%, and quarterly earnings saw a YoY growth of -81.80%.

How much of NBIX stock is held by insiders and institutions?

Wondering who owns Neurocrine stock? Company insiders (like executives and directors) hold about 1.08% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.29%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.